Advertisement

Topics

Companies Related to "Low-Dose IL-2 Plus IFN-Alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma." [Most Relevant Company Matches] [Advanced Search Results] RSS

22:21 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Low-Dose IL-2 Plus IFN-Alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma." found in our extensive corporate database of over 50,000 company records.

Showing "Dose Plus Alpha Immunotherapy Adjuvant Treatment Renal Carcinoma" Companies 1–25 of 3,700+

Extremely Relevant

Intracel

Intracel is a leading commercial-stage biotechnology company focused on the development of immune therapy to treat cancer. The company’s pipeline includes product development programs in active immunotherapy and fully human monoclonal antibodies. Intracel has completed clinical studies in Colon, Renal and Ovarian carcinoma, as well as Melanoma. Business StrategyRestructured company to focus o...


Relevant

Kite Pharma, Inc.

Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of cutting-edge immunotherapeutic products to treat different cancer indications. Kite's lead products include antigens associated with a wide variety of tumor types, and are initially being developed for the treatment of renal cell carcinoma...

Amarillo Biosciences Incorporated

Amarillo Biosciences, Inc., (ABI), is a biopharmaceutical company developing low-dose oral and topical interferon alpha. We are directing our research at the treatment of Behcet's Disease, and oral warts in HIV+ patients and chronic cough in idiopathic pulmonary fibrosis. Low-dose oral interferon is Fundamentally Different from high dose injectable interferon. In this site, we will show the fun...


Alpha-Stim

Alpha-Stim is an industry leader in cranial electrotherapy stimulation (CES) devices, providing treatment for anxiety, depression, insomnia and pain, without the side effects common to prescription medications. Alpha-Stim works by applying a mild electrical current that works effectively in a safe and controlled manner. Created by experienced medical indus...

Alpha Tau Medical

Founded in 2016, Alpha Tau Medical Ltd. is an Israeli medical device company that focuses on research, development and commercialization of the Alpha DaRT for the treatment of solid cancer. Initially developed in 2003 by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University, Alpha DaRT delivers high-precision alpha radiation, that is released...

NephRx Corporation

NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis. Lead product NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical dev...

Alpha-1 Foundation

The mission of the Alpha-1 Foundation is to provide the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency. For information, visit www.alpha-1foundation.org.

The Alpha-1 Project

Mission statement: The Alpha-1 Project will work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the relentless pursuit of cures and therapies for COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency. For more information, visit www.thealpha-1project.com. The Alpha-1 Project is a wholly-owned for...

WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging...

U.S. Renal Care, Inc.

Founded in 2000 by an experienced team of healthcare executives, U.S. Renal Care, Inc. works in partnership with nephrologists to develop, acquire, and operate outpatient treatment centers for persons suffering from chronic kidney failure, also known as End Stage Renal Disease. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis and p...

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals welcomes you to our website to learn about our important novel technology for the treatment of cancer. As part of a worldwide race for a cure for cancer, Actinium Pharmaceuticals Inc. is developing a safe and highly effective therapy for cancer and other life threatening cellular diseases through Alpha Particle Immunotherapy (APIT). APIT is a groundbreaking technology in t...

Alpha-1 Foundation and Foundation for Sarcoidosis Research

The mission of the Alpha-1 Foundation is to provide the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency. For more information, visit www.alpha-1foundation.org.

Cell Medica Limited

Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cancers related to oncogenic viruses. The Company’s lead cell product, CytovirTM CMV, for the treatment and prevention of cytomegalovirus (CMV) infections in patients following al...

Juvaris BioTherapeutics, Inc

Juvaris BioTherapeutics is a clinical stage company developing adjuvanted vaccines to treat infectious diseases. The Company’s lead adjuvant, JVRS-100, is a cationic lipid-DNA complex that is being developed as an adjuvant to improve the effectiveness of existing vaccines and to develop new vaccines against a variety of infectious diseases. Research ...

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism pr...

Advicenne

Advicenne (Euronext: ADVIC) is a pharmaceutical company developing pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company’s lead product is ADV7103 which has demonstrated positive results in a European pivotal phase 3 study in children and adults with distal Tubular Renal Acidosis (dTRA), is also being...

Alpha Pro Tech, Ltd.

Alpha Pro Tech, Ltd. is the parent company of Alpha Pro Tech, Inc., and Alpha ProTech Engineered Products, Inc. Alpha Pro Tech, Inc. develops, manufactures and markets innovative disposable and limited-use protective apparel products for the industrial, clean room, medical and dental markets. In addition, Alpha ProTech Engineered Products, Inc. manufacture...

Allergy Immuno Technologies Incorporated

Allergy Immuno Technologies, Inc. (AIT) and its predecessors commenced development activities in allergy and immune disorder research diagnostic reagents and services in 1980. AIT currently operates a clinical reference laboratory at 1527 Monrovia Avenue, Newport Beach, CA, for allergy and other diagnostic testing services for physicians, other laboratories and pharmaceutical companies. As a resul...

Alpha Therapeutic Corporation

Alpha Therapeutic helps set industry standards with comprehensive donor screening and innovative use of viral inactivation techniques .The company was founded in 1948 in Los Angeles as Courtland Laboratories. In 1978, it was incorporated in California as Alpha Therapeutic Corporation. Alpha's parent company, Mitsubishi Pharma Corporation, is traded on the Japanese Stock Exchange.

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...

NephroPath

Time to diagnosis can have a critical effect on the ultimate outcome of many renal diseases, and when a patient undergoes an invasive procedure such as a renal biopsy, there can be significant anxiety while the results are pending. Over the last 14 years, Dr. Patrick Walker, our Director and one of the nation's leading renal pathologists, has developed a unique system for rapid processing of renal...

Northwest Biotherapeutics

Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against ...

Immunomic Therapeutics, Inc. and ZENOAQ

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with ...

Alpha Water Systems Inc

For over 20 years, the staff at Alpha Water Systems has been helping consumers with various water problems all across the United States through a network of retail locations. We created this site in 1995 to combine the power of the internet with our vast expertise of water treatment to reach even more people across the globe!

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...


More From BioPortfolio on "Low-Dose IL-2 Plus IFN-Alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma."

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks